摘要：目的 探究急性髓系白血病（acute myeloid leukemia, AML）患者外周血视黄醇结合蛋白（retinol-binding protein, RBP）表达水平及其与患者临床特征的相关性。方法 分析AML患者、良性血液病患者及健康体检者外周血RBP表达水平及其与AML患者年龄、性别、FAB(French-American-British)分型、细胞遗传学及基因突变的相关性。结果 AML患者外周血RBP表达水平明显低于良性血液病患者及健康对照组。M 及M 患者RBP表达水平与白细胞计数呈负相关，R分别为- 4 5 0.499与-0.412，P分别为0.036与0.029。APL(acute promyelocytic leukemia)患者RBP表达水平明显高于M （u=-2.085，P= 2 0.037）、M4（u=-3.085，P=0.002）及M5（u=-2.249，P=0.024）患者，而其他FAB各亚型间RBP表达水平无明显差异（全部P>0.05） 。老年AML患者RBP表达水平明显高于中年（t=2.572，P=0.011）及儿童患者（t=2.284，P=0.049）。FLT3-ITD 突变患者RBP表达水平明显低于无突变者（u=-2.173，P=0.030）。结论 RBP不仅可作为AML患者的营养指标之一，其表达水平及其与AML患者临床特征的相关性还可能为AML的优化治疗提供有价值的参考。

Abstract: Objective To explore the expression level of retinol-binding protein (RBP) in peripheral blood of patients with acute myeloid leukemia (AML) and its relationships with clinical characteristics of the patients. Methods The expression level of RBP in patients with AML, those with benign hematopathy, and healthy subjects was analyzed. Further, the relationships between age, gender, cytogenetics, French-American-British (FAB) subtypes, molecular mutations, and RBP expression level were analyzed. Results Compared with AML patients, RBP expression level was significantly higher in healthy subjects and those with benign hematopathy. A significantly negative association was observed in patients with M (r=-0.499, P=0.036) and M (r=-0.412, P= 4 5 0.029). Acute promyelocytic leukemia (APL) patients showed higher RBP level compared with those of M (u=-2.085, P=0.037), M 2 4 (u=-3.085, P=0.002), and M (u=-2.249, P=0.024). However, no difference was observed between other FAB subtypes (all P > 0.05). 5 Elderly AML patients had higher RBP level compared with children (t=2.284, P=0.049) and adult patients (t=2.572, P=0.011). Patients carring FLT3-ITD mutation presented with lower RBP level than those without (u=-2.173, P=0.030). Conclusion RBP is not only a nutritional index for AML, but its expression level and relationships with clinical characteristics of AML might offer beneficial information for optimizing AML treatment.